RxDoctor Payments Data

Geoffrey Hoover, MD

Family Medicine · Edmond, OKNPI 1720039100

Payments from drug & device makers

$6,985in general payments, 2019–2025

Across 483 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$981
  • GSK$830
  • AbbVie$784
  • Novo Nordisk$652
  • Abbott$386
  • AstraZeneca$369
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,981100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,985 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$190,502
Medicare patients
513
Services billed
4,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$143,165
MounjaroTirzepatide114$122,620
EliquisApixaban65$69,364
JardianceEmpagliflozin27$39,275
FarxigaDapagliflozin Propanediol25$37,726
LinzessLinaclotide44$32,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$31,565
TrulicityDulaglutide13$30,096
MyrbetriqMirabegron36$24,570
XareltoRivaroxaban22$20,722
RybelsusSemaglutide12$16,472
Spiriva RespimatTiotropium Bromide30$15,951
Breo ElliptaFluticasone/Vilanterol28$15,408
VraylarCariprazine Hcl11$14,961
Tresiba Flextouch U-100Insulin Degludec29$13,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$652$159,637126 claims
Lilly USA, LLCMounjaro, Trulicity$224$152,716127 claims
PfizerEliquis, Premarin$981$76,85481 claims
Boehringer IngelheimJardiance, Spiriva Respimat$73$55,22557 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$369$51,60957 claims
AbbVieLinzess, Vraylar, Synthroid$784$50,10582 claims
GSKTrelegy Ellipta, Breo Ellipta$830$46,97359 claims
Astellas Pharma US IncMyrbetriq$216$24,57036 claims
Johnson & JohnsonXarelto$24$20,72222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →